NXPZ-2

NXPZ-2 is an orally active Keap1-Nrf2 protein–protein interaction (PPI) inhibitor with a Ki value of 95 nM, EC50 value of 120 and 170 nM. NXPZ-2 can dose-dependently ameliorate Aβ[1-42]-Induced cognitive dysfunction, improve brain tissue pathological changes in Alzheimer’s disease (AD) mouse by increasing neuron quantity and function. NXPZ-2 can inhibit oxidative stress by increasing Nrf2 expression levels and promoting its cytoplasm to nuclear translocation, which is helpful for Keap1-Nrf2 PPI inhibitors and AD associated disease research[1].

Product Specifications

CAS Number

[2254492-08-3]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Keap1-Nrf2

Type

Reference compound

Related Pathways

NF-κB

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/nxpz-2.html

Purity

98.18

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(N)CN(C1=C2C=CC=CC2=C(N(CC(N)=O)S(=O)(C3=CC=C(N)C=C3)=O)C=C1)S(=O)(C4=CC=C(OC)C=C4)=O

Molecular Formula

C27H27N5O7S2

Molecular Weight

597.66

Precautions

H302, H315, H319

References & Citations

[1]Yi Sun, et al. Direct inhibition of Keap1-Nrf2 Protein-Protein interaction as a potential therapeutic strategy for Alzheimer's disease. Bioorg Chem. 2020 Oct;103:104172.